Phase 2 Chronic Kidney Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who have chronic kidney disease (CKD) with reduced kidney function, measured by a specific kidney test result falling within a certain range, or a moderately reduced kidney function with significant protein in the urine (confirm exact values with trial site)
- People already taking a blood pressure/kidney-protecting medication (ACE inhibitor or ARB) at the appropriate dose for at least 4 weeks before joining, if that medication is medically suitable for them
- People with type 2 diabetes who have been on a stable diabetes medication regimen for more than 30 days before their screening appointment
- Female patients who are either past menopause (for at least 1 year), have had a surgical procedure that prevents pregnancy, or are using an approved form of contraception throughout the study and for 30 days after it ends
- People who are able to understand and read Danish
- People who have signed a consent form agreeing to participate
Who may not be able to join:
- People who have type 1 diabetes
- People with type 2 diabetes who have a history of a serious complication called diabetic ketoacidosis
- People who are currently receiving dialysis (kidney replacement treatment)
- People who have previously had an organ transplant
- People who have taken an SGLT2 inhibitor medication within the 8 weeks before enrolling
- People with a known allergy or sensitivity to SGLT2 inhibitors or any ingredients in the placebo
- People who have had a heart attack, unstable chest pain, stroke, or mini-stroke within 12 weeks before enrolling
- People who have had a heart procedure (such as a stent, bypass surgery) or a heart valve repair or replacement within 12 weeks before enrolling
- People with a serious non-kidney, non-heart medical condition that a doctor judges may limit life expectancy to less than 2 years
- People with significant liver problems, based on specific blood test results at the time of enrolment (confirm details with trial site)
- People with known blood-borne illnesses such as Hepatitis A, B, C, D, or E, HIV, Ebola, or Lassa fever
- Female patients who are pregnant, breastfeeding, or planning to become pregnant during the study or within 6 months after it ends
- People who have taken part in another clinical trial involving an investigational treatment within the last month before enrolling
- People who are unable to follow the study instructions, attend follow-up appointments, or complete the study for any reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Tor Biering-Sørensen, Research Director
Phone: +4531360232
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in LV mass index assessed by echocardiography at 6 months
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.